These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31215546)

  • 1. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(3):113-120. PubMed ID: 31393455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of brimonidine in children with glaucoma.
    Enyedi LB; Freedman SF
    J AAPOS; 2001 Oct; 5(5):281-4. PubMed ID: 11641636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brimonidine.
    Bakheit AH; Alomar AM; Darwish H; Alkahtani HM
    Profiles Drug Subst Excip Relat Methodol; 2023; 48():1-37. PubMed ID: 37061271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brimonidine tartrate for the treatment of glaucoma.
    Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
    Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic beta-blocker therapy and brimonidine and timolol.
    Coulibaly R
    Ophthalmology; 2001 Aug; 108(8):1368. PubMed ID: 11470677
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
    Carlsson AM; Chauhan BC; Lee AA; Leblanc RP
    Am J Ophthalmol; 1999 Dec; 128(6):697-701. PubMed ID: 10612505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
    Wheeler LA; Woldemussie E
    Eur J Ophthalmol; 2001; 11 Suppl 2():S30-5. PubMed ID: 11592528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
    Katz LJ
    Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brimonidine for glaucoma.
    Rahman MQ; Ramaesh K; Montgomery DM
    Expert Opin Drug Saf; 2010 May; 9(3):483-91. PubMed ID: 20367525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
    Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y
    Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
    Kaneko E; Wada T; Minagawa Y; Inoue Y
    Nihon Yakurigaku Zasshi; 2012 Oct; 140(4):177-82. PubMed ID: 23059902
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical evaluation of brimonidine.
    Burke J; Schwartz M
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S9-18. PubMed ID: 8970245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anterior uveitis as a side effect of topical brimonidine.
    Byles DB; Frith P; Salmon JF
    Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.